J&J locked arms with Emergent in April 2020, enlisting the lesser-known company to manufacture its vaccine. At the time, Emergent’s Bayview facility wasn’t scaled for making millions of doses of vaccine, according to the FDA records, which describe the plant as a contract testing laboratory that “did not manufacture products for distribution.”
